OBOliver Bock

Oliver Bock

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oliver Bock has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Genetic variations in the HSD11B1 gene in patients treated with glucocorticoids show associations with bone mineral density

    by Heide Siggelkow, Martina Blaschke, Gabriele Armbrecht, Friederike Thomasius, Oliver Bock, Mladen Tzvetkov, Claus-C Gluer, Dieter Felsenberg

    Introduction: Physiological glucocorticoids play an essential role in bone formation but can cause osteoporosis if present in excess. The key enzyme converting inactive cortisone into the active cortisol and vice versa is 11-beta-hydroxy-steroid-dehydrogenase (11β-HSD1). We have reported that genetic variations in the HSD11B1 gene correlate with increased cortisol levels in dexamethasone suppression and with changes in bone mineral density (BMD) suggesting individual differences in 11β-HSD1 activity caused by polymorphisms. In this study we investigated the effect of HSD11B1 SNPs on BMD in patients on glucocorticoid therapy. Methods: In 246 patients treated with different glucocorticoids the HSD11B1 SNPs rs11811440, rs1000283 und rs932335 were determined. Patients received glucocorticoids due to rheumatoid arthritis or asthma (64%), or other rheumatic, gastrointestinal or pulmonary disorders. An equivalent glucocorticoid dose was calculated for the different glucocorticoids used. BMD of the spine or femoral neck, and the number of fractures and falls were correlated to the HSD11B1 SNPs. Results: BMD, the number of fractures and falls did not show an association with daily or cumulative equivalent dose or type of glucocorticoid. Since the three genetically linked SNPs in intron 5 of the 11β-HSD1 gene – rs11811440, rs1000283, and rs932335 HSD11B1 highly correlated, only rs11811440 was further analyzed. In patients treated with the glucocorticoids prednisolone or methylprednisolone the presence of the A-allele was associated with lower BMD levels. Discussion: Our results suggest that in patients treated with glucocorticoids the function of 11β-HSD1 is dependent on HSD11B1 polymorphisms. Hence, inactivation of prednisolone or methylprednisolone by 11β-HSD1 would be the crucial step for BMD levels in glucocorticoid-treated individuals.

  • Endokrinologie. Effektivität und Nebenwirkungen der medikamentösen Osteoporosetherapie

    by Oliver Bock

    Die Darstellungen berücksichtigen – soweit nicht anders angegeben – vor allem die Bewertungen und Empfehlungen der aktuellen Leitlinien des Dachverbands Osteologie e. V. (DVO) zur Prävention, Diagnostik und Therapie der Osteoporose, mit entsprechendem Empfehlungsgrad in Klammern. Die Leitlinien werden fortlaufend auf Basis der DELBI-Kriterien aktualisiert und planmäßig alle 3 Jahre vollständig überarbeitet (zuletzt 2009). Die S3-Leitlinie gibt praxisnahe Empfehlungen unter Berücksichtigung von Kosten-Nutzen-Aspekten für die Prävention von osteoporotischen Frakturen bei Risikopatienten. In der Osteoporose-Leitlinie werden nicht medikamentöse Basistherapien (Kapitel 10.1), Indikationen für eine spezifische medikamentöse Therapie der Osteoporose (Kapitel 10.3) und Evidenz der Präparate mit nachweislich bester Frakturrisiko senkender Wirkung (Kapitel 10.4.) ausführlich dargestellt. Die nächste Aktualisierung steht für 2012 an.

  • Die Wirkung der antiresorptiven Therapie am Knochen

    by O. Bock

    Die meisten aktuellen Ansätze zur medikamentösen Behandlung des systemischen Knochenverlustes bei Osteoporose–wie Östrogene und SERM, aber vor allem Bisphosphonate und Denosumab – zielen auf eine Inhibition der Osteoklasten, der den Knochen abbauenden Zellen, ab. Stickstoffhaltige Bisphosphonate wirken durch ihre starke Bindung an der Knochenoberfläche und eine Hemmung der Osteoklastenfunktion vorwiegend über die Inhibierung der Farnesyl-Pyrophosphat-Synthase. Denosumab als vollhumaner monoklonaler Antikörper bewirkt hingegen eine gezielte Hemmung von RANK-Ligand und damit der Osteoklastendifferenzierung und -aktivierung sowie letztlich eine Reduktion der Osteoklastenzahl an der Knochenoberfläche. Bisphosphonate wie Alendronat, Risedronat, Ibandronat und Zoledronat sowie eben auch Denosumab zeigten in klinischen Studien robuste Ergebnisse bezüglich einer signifikanten Reduktion des Frakturrisikos. Ein grundlegendes Wissen um die unterschiedliche Wirkungsweise ist Voraussetzung, um einen potenziell kausalen Zusammenhang zwischen Antiresorptiva und Kieferosteonekrosen (ONJ) verstehen und daraus differenzierte und effektive Präventions- und Therapiestrategien entwickeln zu können. In order to treat systemic bone loss in osteo - porosis, most approaches target the osteoclasts – the cells resorbing bone. Drugs inhibiting the differentiation, activity and/or survival of osteoclasts have, thus, become a fundamental option for the prevention and treatment of osteoporosis. In general, this class includes estrogens and selective estrogen receptor modulators, but, first of all, bisphosphonates and denosumab. Bisphosphonates are currently the most widely used antiresorptive therapy. They act by binding to bone and interfering with osteoclast function. The nitrogen-containing bisphosphonates act as inhibitors of farnesyl-pyro - phosphate synthase, which leads to inhibition of the prenylation of intracellular proteins. The recent discovery of the RANK/RANKL/OPG system and its essential role in the osteoclast differentiation, activity and survival, have led to the development of denosumab – an innovative treatment option. This fully human monoclonal antibody acts by binding to and inhibiting RANK-Ligand (RANKL), leading to the inhibition of osteoclast differentiation, its activity and survival and, finally, to a loss of osteoclasts from bone surfaces. Bisphosphonates, such as alendronate, risedronate, ibandronate and zoledronate, as well as the RANKLinhibitor denosumab have been approved for the treatment of osteoporosis and have shown robust efficacy data in reference to fracture prevention. The key pharmacological differences between denosumab and bisphosphonates are a result of the distribution of the drugs within bone and their effects on precursors and mature osteoclasts. This may explain differences in the degree of reduction of bone resorption, their potential differential effects on trabecular and cortical bone, and the reversibility of their actions. Basic knowledge of the differences in mode of action of these drugs is also essential to understanding of their potential association with osteonecrosis of the jaw (ONJ) and to development of differentiated and sufficient ONJ prevention and treatment strategies.


  • Open Access

    Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice

    by Oliver Bock, Dieter Felsenberg

    Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice Oliver Bock, Dieter FelsenbergCenter for Muscle and Bone Research, Campus Benjamin Franklin, Charité – University Medicine Berlin, Berlin, Germany Nitrogen-containing bisphosphonates are potent inhibitors of osteoclastic bone resorption. With their individually proven efficacy to significantly reduce the incidence of vertebral and/or non-vertebral fractures and with their overall beneficial safety profile, alendronate, ibandronate, risedronate, and zoledronate are considered today a treatment of first choice in postmenopausal osteoporosis. However, treatment effects in an individual patient and cost-effectiveness in public health perspective are vitally dependent on the long-term patient adherence as well as on compliance and persistence. As compliance and persistence with daily oral bisphosphonates are shown to be suboptimal in many patients, leading to an increased fracture incidence in non-compliant patients, there is a need to improve overall adherence for bisphosphonate treatment in order to achieve maximum treatment effects. One option is to extend dosing intervals to weekly (alendronate, risedronate) or monthly (ibandronate) oral regimens. Less frequent oral regimens are generally preferred by majority of patients. Another alternative is intravenous, instead of oral application (ibandronate, zoledronate). Treatment acceptance could be further improved by IV bisphosphonates with their benefit of only quarterly, or even once-yearly, application. Treatment decisions should be based on anti-fracture efficacy data first. In addition, to ensure best possible patient adherence and maximum treatment benefits, physicians should consider individual patient conditions affecting compliance and persistence as well as patient preferences.Keywords: postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, adherence, dosing frequencies, patient considerations